Determination of Rubella Virus-Specific Cell-Mediated Immunity Using IFNγ-ELISpot

被引:5
作者
Allmendinger, J. [1 ]
Paradies, F. [1 ]
Kamprad, M. [2 ]
Richter, T. [1 ]
Pustowoit, B. [1 ]
Liebert, U. G. [1 ]
机构
[1] Univ Leipzig, Inst Virol, Leipzig, Germany
[2] Univ Leipzig, Inst Clin Immunol & Transfus Med, Leipzig, Germany
关键词
rubella virus; cell-mediated immunity; ELISpot; LINKED IMMUNOSPOT ASSAY; MEMORY T-CELLS; PERIPHERAL-BLOOD; LYMPHOPROLIFERATIVE RESPONSES; INFLUENZA VACCINATION; HEALTHY-INDIVIDUALS; MEASLES-VACCINE; ANTIGEN; INTERFERON; SEROCONVERSION;
D O I
10.1002/jmv.21621
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Immunity to rubella virus (RV) is conventionally determined by measuring specific immunoglobulin G (IgG). However, several individuals may be considered immune despite undetectable antibody levels. In the present study RV-specific interferon-gamma (IFN gamma)-ELISpot and rubella-IgG-ELISA were compared in 75 young adults aged between 20 and 30 years. In a subgroup, not only rubella-like particles (RLP), but also HPV77 rubella vaccine derived antigen was used in IFN gamma-ELISpot. The results from both, ELISA and ELISpot were independent of previous encounter to RV (vaccination, exanthematous disease, or childhood infection). There was no difference between RLP and RV vaccine antigen in IFN gamma-ELISpot response, and there was no correlation between IFN gamma-ELISpot and RV-specific IgG levels. IFN gamma-producing cells were found in 78.7% of all tested persons, and 83.8% of them were positive in ELISA. In almost all individuals seronegative for RV antibody, IFN gamma-producing cells were detected. Considering both humoral and cell-mediated immune responses, a positive RV immune reaction was seen in 98.6%. The results indicate that the IFN gamma-ELISpot can provide valuable additional information in seronegative individuals. J. Med. Virol. 82:335-340, 2010. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:335 / 340
页数:6
相关论文
共 35 条
[1]   Anti-HBs cellular immune response in kidney recipients before and 4 months after transplantation [J].
Aguilar, P ;
Renoult, E ;
Jarrosson, L ;
Kolopp-Sarda, MN ;
Mathieu, CP ;
Faure, GC ;
Kessler, M ;
Bene, MC ;
Kohler, C ;
De March, AK .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (06) :1117-1122
[2]  
Al-Sherbiny M, 2005, AM J TROP MED HYG, V73, P44
[3]   Identification of dominant optimal HLA-B60-and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: Rapid characterization of CTL responses by enzyme-linked immunospot assay [J].
Altfeld, MA ;
Trocha, A ;
Eldridge, RL ;
Rosenberg, ES ;
Phillips, MN ;
Addo, MM ;
Sekaly, RP ;
Kalams, SA ;
Burchett, SA ;
McIntosh, K ;
Walker, BD ;
Goulder, PJR .
JOURNAL OF VIROLOGY, 2000, 74 (18) :8541-8549
[4]   RUBELLA VACCINES - PAST, PRESENT AND FUTURE [J].
BEST, JM .
EPIDEMIOLOGY AND INFECTION, 1991, 107 (01) :17-30
[5]   INFECTIOUSNESS OF RUBELLA AND POSSIBILITY OF REINFECTION [J].
BRODY, JA .
AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1966, 56 (07) :1082-+
[6]  
BUIMOVICIKLEIN E, 1985, REV INFECT DIS, V7, pS123
[7]   PERSISTENT RUBELLA-VIRUS INFECTION ASSOCIATED WITH CHRONIC ARTHRITIS IN CHILDREN [J].
CHANTLER, JK ;
TINGLE, AJ ;
PETTY, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (18) :1117-1123
[8]   CELLULAR AND HUMORAL IMMUNE-RESPONSES TO RUBELLA-VIRUS STRUCTURAL PROTEIN-E1, PROTEIN-E2, AND PROTEIN-C [J].
CHAYE, HH ;
MAURACHER, CA ;
TINGLE, AJ ;
GILLAM, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (09) :2323-2329
[9]   A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays [J].
Currier, JR ;
Kuta, EG ;
Turk, E ;
Earhart, LB ;
Loomis-Price, L ;
Janetzki, S ;
Ferrari, G ;
Birx, DL ;
Cox, JH .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 260 (1-2) :157-172
[10]   Age-related impaired type 1 T cell responses to influenza: Reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly [J].
Deng, YP ;
Jing, Y ;
Campbell, AE ;
Gravenstein, S .
JOURNAL OF IMMUNOLOGY, 2004, 172 (06) :3437-3446